More Potential FDA Opioid Delays In Nektar's Wake [Seeking Alpha]
Nektar Therapeutics (NKTR)
Last nektar therapeutics earnings: 2/27 04:15 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.nektar.com/investor-relations
Company Research
Source: Seeking Alpha
More Potential FDA Opioid Delays In Nektar's Wake Summary The FDA recently informed Nektar Therapeutics that a committee meeting for its new opioid drug would be delayed. Nektar's shares dived as a result. Here's a look at other companies in late development stages for new opioids that may see similar delays and similar declines. The attack on opioids is intensifying once again, and the circle of companies falling victim is widening. On Aug. 1, Reuters reported that the State of Oklahoma is now making its final efforts JNJ Companies on the verge of approvals for this class of drugs are getting hit in the backlash. The latest is Nektar Therapeutics (NASDAQ: NKTR just postponed The FDA seems to be getting cold feet in response to recent developments in the opioid space, and there is little to nothing that Nektar can do about it. Worse for Nektar, the FDA also indicated that it may not be able to meet the PDUFA deadline for its decision on the drug. The stock fell 11% on the news to end
Show less
Read more
Impact Snapshot
Event Time:
NKTR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NKTR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NKTR alerts
High impacting Nektar Therapeutics news events
Weekly update
A roundup of the hottest topics
NKTR
News
- Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence [Yahoo! Finance]Yahoo! Finance
- Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) ConvergencePR Newswire
- Nektar Therapeutics (NASDAQ:NKTR) Just Reported And Analysts Have Been Lifting Their Price Targets [Yahoo! Finance]Yahoo! Finance
- Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Highlights: Strategic Moves and Financial Outlook [Yahoo! Finance]Yahoo! Finance
- Nektar Therapeutics Reports Third Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
NKTR
Earnings
- 11/7/24 - Beat
NKTR
Sec Filings
- 11/20/24 - Form 4
- 11/20/24 - Form 4
- 11/20/24 - Form 4
- NKTR's page on the SEC website